23 research outputs found

    Practical Peptide Synthesis Mediated by a Recyclable Hypervalent Iodine Reagent and Tris(4-methoxyphenyl)phosphine

    No full text
    6-(3,5-Bis­(trifluoromethyl)­phenyl)-1<i>H</i>,4<i>H</i>-2aλ<sup>3</sup>-ioda-2,3-dioxacyclopenta­[<i>hi</i>]­indene-1,4-dione (<i>p</i>-BTFP-iodosodilactone, <b>1a</b>) was synthesized and demonstrated to be an efficient hypervalent iodine­(III) reagent for the synthesis of dipeptides from various standard amino acids, including sterically hindered amino acids, in good to high yields within 30 min in the presence of tris­(4-methoxyphenyl)­phosphine. In addition, the combined system of <b>1a/</b>(4-MeOC<sub>6</sub>H<sub>4</sub>)<sub>3</sub>P was used to synthesize the pentapeptide leu-enkephalin in protected form. It is worth noting that <b>1a</b> can be regenerated readily after reaction

    A Mild and Efficient Direct α-Amination of β-Dicarbonyl Compounds Using Iodosobenzene and <i>p</i>-Toluenesulfonamide Catalyzed by Perchlorate Zinc Hexahydrate

    No full text
    A direct α-amination of β-dicarbonyl compounds has been achieved by using iodosobenzene (PhIO) as an oxidant and <i>p</i>-toluenesulfonamide (TsNH<sub>2</sub>) as an aminating reagent in the presence of a catalytic amount of perchlorate zinc hexahydrate. The present amination reaction proceeds quickly at rt (<30 min needed for most tested substrates) to provide the corresponding α-<i>N</i>-tosylamido β-dicarbonyl compounds in high to excellent yields

    Robotic radical hysterectomy is superior to laparoscopic radical hysterectomy and open radical hysterectomy in the treatment of cervical cancer

    No full text
    <div><p>Objective</p><p>Cervical cancer (CC) continues to be a global burden for women, with higher incidence and mortality rates reported annually. Many countries have witnessed a dramatic reduction in the prevalence of CC due to widely accessed robotic radical hysterectomy (RRH). This network meta-analysis aims to compare intraoperative and postoperative outcomes in way of RRH, laparoscopic radical hysterectomy (LTH) and open radical hysterectomy (ORH) in the treatment of early-stage CC.</p><p>Methods</p><p>A comprehensive search of PubMed, Cochrane Library and EMBASE databases was performed from inception to June 2016. Clinical controlled trials (CCTs) of above three hysterectomies in the treatment of early-stage CC were included in this study. Direct and indirect evidence were incorporated for calculating values of weighted mean difference (WMD) or odds ratio (OR), and drawing the surface under the cumulative ranking curve (SUCRA).</p><p>Results</p><p>Seventeen 17 CCTs were ultimately enrolled in this network meta-analysis. The network meta-analysis showed that patients treated by RRH and LRH had lower estimated blood loss compared to patients treated by ORH (WMD = -399.52, 95% CI = -600.64~-204.78; WMD = -277.86, 95%CI = -430.84 ~ -126.07, respectively). Patients treated by RRH and LRH had less hospital stay (days) than those by ORH (WMD = -3.49, 95% CI = -5.79~-1.24; WMD = -3.26, 95% CI = -5.04~-1.44, respectively). Compared with ORH, patients treated with RRH had lower postoperative complications (OR = 0.21, 95%CI = 0.08~0.65). Furthermore, the SUCRA value of three radical hysterectomies showed that patients receiving RRH illustrated better conditions on intraoperative blood loss, operation time, the number of resected lymph nodes, length of hospital stay and intraoperative and postoperative complications, while patients receiving ORH demonstrated relatively poorer conditions.</p><p>Conclusion</p><p>The results of this meta-analysis confirmed that early-stage CC patients treated by RRH were superior to patients treated by LRH and ORH in intraoperative blood loss, length of hospital stay and intraoperative and postoperative complications, and RRH might be regarded as a safe and effective therapeutic procedure for the management of CC.</p></div

    SUCRA values of three treatment modalities under six endpoint outcomes.

    No full text
    <p>SUCRA values of three treatment modalities under six endpoint outcomes.</p

    Weighted mean difference or odds ratio (95% confidence intervals) of three treatment modalities of six endpoint outcomes.

    No full text
    <p>Weighted mean difference or odds ratio (95% confidence intervals) of three treatment modalities of six endpoint outcomes.</p

    WMD/OR values and <i>P</i> values of direct and indirect pairwise comparisons of three treatment modalities under six endpoint outcomes.

    No full text
    <p>WMD/OR values and <i>P</i> values of direct and indirect pairwise comparisons of three treatment modalities under six endpoint outcomes.</p

    Pairwise meta-analysis in terms of six endpoints.

    No full text
    <p>Pairwise meta-analysis in terms of six endpoints.</p
    corecore